Secondary hyperparathyroidism

Report Year

Trial Code

Trial Title

Clinicaltrials.gov

EudraCTno.

Source

2007

OA 0301 DE

Efficacy of p.o. and i.v. alfacalcidol in the treatment of secondary hyperparathyroidism in patients with chronic renal failure

N/A

N/A

Summary

Report

Active Substance

alfacalcidol

LEO Pharma Product

One-Alpha®

Formulation

capsule & injectional

Trial Phase

3

Population

adults

2000

OA 9601 INT

Evaluation of 1 mg alfacalcidol daily (4 x 0.25 mg capsules) as prophylaxis of bone loss in patients treated with systemic corticosteroids

N/A

N/A

Summary

Report

Active Substance

alfacalcidol

LEO Pharma Product

One-Alpha®

Formulation

capsule

Trial Phase

3

Population

adults

 

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.